Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives $13.60 Consensus Price Target from Brokerages

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have earned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $13.60.

OBIO has been the topic of several research analyst reports. Barclays increased their price objective on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. B. Riley Financial lowered their price target on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Wall Street Zen cut Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Orchestra BioMed in a research report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Orchestra BioMed in a research note on Thursday, May 14th.

Orchestra BioMed Stock Performance

OBIO opened at $3.86 on Wednesday. Orchestra BioMed has a 12-month low of $2.20 and a 12-month high of $5.42. The stock has a market cap of $231.14 million, a price-to-earnings ratio of -3.98 and a beta of 0.49. The business has a 50 day moving average of $3.96 and a 200-day moving average of $4.12. The company has a quick ratio of 7.01, a current ratio of 7.03 and a debt-to-equity ratio of 0.35.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.92 million. On average, equities research analysts expect that Orchestra BioMed will post -1.47 earnings per share for the current year.

Insider Buying and Selling at Orchestra BioMed

In other Orchestra BioMed news, Director Jason Aryeh bought 8,971 shares of Orchestra BioMed stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $3.90 per share, with a total value of $34,986.90. Following the completion of the transaction, the director owned 117,453 shares in the company, valued at $458,066.70. The trade was a 8.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Darren Sherman sold 15,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $3.87, for a total transaction of $58,050.00. Following the completion of the sale, the insider directly owned 1,184,327 shares of the company’s stock, valued at approximately $4,583,345.49. The trade was a 1.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have bought a total of 39,636 shares of company stock valued at $158,081 in the last ninety days. 7.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Orchestra BioMed

Institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Orchestra BioMed during the 4th quarter worth approximately $38,000. Virtu Financial LLC bought a new stake in shares of Orchestra BioMed in the fourth quarter valued at approximately $57,000. Creative Planning bought a new stake in shares of Orchestra BioMed in the second quarter valued at approximately $40,000. XTX Topco Ltd acquired a new stake in Orchestra BioMed during the second quarter worth approximately $45,000. Finally, Balyasny Asset Management L.P. acquired a new stake in Orchestra BioMed during the fourth quarter worth approximately $76,000. Institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.